Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REL-(9R , 12S ) - 9 ,10 ,11 ,12-tetrahydro - 9 ,12 - epoxy - 1 H-diindolo [123-fg :32'21'-kl ] pyrrolo [34-i ][16 ] benzodiazocine – 13(2 H ) dione is a synthetic small molecule belonging to the indolocarbazole class of polycyclic aromatic compounds.[1][7] It acts as an inhibitor of serine/threonine-protein kinase Chk1 (Checkpoint kinase 1), a key regulator in cell cycle control and DNA damage response pathways.[1] The compound is primarily studied as an experimental tool for research purposes and has not been approved for clinical use. Its main mechanism involves inhibition of Chk1 activity in human cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on REL-(9R,12S)-9,10,11,12-tetrahydro-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1,3(2H)-dione.